Cargando…
Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype
The probable-amnestic (Pr-a) mild cognitive impairment (MCI)-storage subtype is a phenotype with 8.5 times more risk of conversion to dementia, mainly Alzheimer’s disease (AD), than the possible non-amnestic (Pss-na) MCI. The aim of this study was to find the optimized cognitive composites (CCs) dom...
Autores principales: | Espinosa, Ana, Alegret, Montserrat, Pesini, Pedro, Valero, Sergi, Lafuente, Asunción, Buendía, Mar, San José, Itziar, Ibarria, Marta, Tejero, Miguel A., Giménez, Joan, Ruiz, Susana, Hernández, Isabel, Pujadas, Francesc, Martínez-Lage, Pablo, Munuera, Josep, Arbizu, Javier, Tárraga, Lluis, Hendrix, Suzanne B., Ruiz, Agustín, Becker, James T., Landau, Susan M., Sotolongo-Grau, Oscar, Sarasa, Manuel, Boada, Mercè |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366247/ https://www.ncbi.nlm.nih.gov/pubmed/28269787 http://dx.doi.org/10.3233/JAD-161223 |
Ejemplares similares
-
Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2013) -
Correction: Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2014) -
Association between cell-bound blood amyloid-β(1–40) levels and hippocampus volume
por: Sotolongo-Grau, Oscar, et al.
Publicado: (2014) -
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2019) -
Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
por: Lacosta, Ana-María, et al.
Publicado: (2018)